Key result
High TIMP-1 expression is independently associated with poor overall survival in patients with non-small cell lung cancer (HR 1.60; 95% CI 1.50-1.69; P<0.00001).
Why the study?
Does high TIMP-1 expression predict poor overall survival in patients with NSCLC?
Meta-Analysis (n=3,194)
Does high TIMP-1 expression predict poor overall survival in patients with NSCLC?
Hazard Ratio: 1.6 (95% CI 1.5–1.69)
p-value: p=< 0.00001
High TIMP-1 expression is a significant predictor of poor overall survival in patients with non-small cell lung cancer.
High TIMP-1 expression was associated with poor NSCLC prognosis; leaves open its role as a biomarker pending prospective validation.
BACKGROUND AND OBJECTIVES: Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) is a multifunctional natural matrixin inhibitor that is generally considered a negative regulator of cancer metastasis. Clinical studies reporting the prognostic value of TIMP-1 in Non-small Cell Lung Cancer (NSCLC) are inconsistent. Therefore, the present study aimed to determine the prognostic impact of TIMP-1 expression in NSCLC. METHODS: Appropriate studies with full-text articles were identified in searches of the China National Knowledge Infrastructure (CNKI), Cochrane Library, PubMed, and Web of Science databases up to March 7, 2018. The pooled Hazard Ratio (HR) of overall survival with a 95% confidence interval (95% CI) was employed to assess the relationship between the expression of TIMP-1 and NSCLC patient survival. RESULTS: The meta-analysis comprised 40 studies including 3,194 patients. Study outcomes indicated that high TIMP-1 expression is independently associated with poor overall survival (HR: 1.60; 95% CI: 1.50, 1.69; P < 0.00001) with 61% of heterogeneity. In addition, we analyzed subgroups, including ethnicities, histological types, percentage of TIMP-1 expression levels, specimens, and tumor stage. All results were statistically significant. The outcome of our meta-analysis indicates that high expression levels of TIMP-1 are correlated with poor prognosis in patients with NSCLC. CONCLUSION: Expression levels of TIMP-1 represent a potential prognostic biomarker in NSCLC patients in addition to being a possible therapeutic target.
No takes yet. Share an insight, caveat, or question.
Selvaraj et al. (2018) conducted a meta-analysis in Non-small Cell Lung Cancer (NSCLC) (n=3,194). High TIMP-1 expression was evaluated on overall survival (HR 1.60, 95% CI 1.50, 1.69, p=< 0.00001). High TIMP-1 expression is independently associated with poor overall survival in patients with non-small cell lung cancer (HR 1.60; 95% CI 1.50-1.69; P<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: